Biogen Inc.
BIIB
$199.36
$1.410.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.48B | 2.28B | 2.53B | 2.65B | 2.43B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.48B | 2.28B | 2.53B | 2.65B | 2.43B |
| Cost of Revenue | 610.20M | 443.40M | 508.60M | 946.20M | 577.90M |
| Gross Profit | 1.87B | 1.84B | 2.03B | 1.70B | 1.85B |
| SG&A Expenses | 607.30M | 685.20M | 592.80M | 581.30M | 572.50M |
| Depreciation & Amortization | 136.50M | 132.20M | 135.70M | 127.40M | 111.80M |
| Other Operating Expenses | 74.20M | 69.90M | 87.20M | 75.00M | 58.10M |
| Total Operating Expenses | 1.91B | 1.83B | 1.76B | 1.73B | 1.75B |
| Operating Income | 567.40M | 447.70M | 778.60M | 915.60M | 676.60M |
| Income Before Tax | 377.70M | -56.00M | 557.30M | 744.00M | 311.20M |
| Income Tax Expenses | 58.20M | -7.10M | 90.80M | 109.20M | 70.70M |
| Earnings from Continuing Operations | 319.50M | -48.90M | 466.50M | 634.80M | 240.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 319.50M | -48.90M | 466.50M | 634.80M | 240.50M |
| EBIT | 567.40M | 447.70M | 778.60M | 915.60M | 676.60M |
| EBITDA | 771.80M | 647.90M | 980.80M | 1.11B | 859.80M |
| EPS Basic | 2.17 | -0.33 | 3.18 | 4.33 | 1.65 |
| Normalized Basic EPS | 2.25 | 1.80 | 3.19 | 3.68 | 2.77 |
| EPS Diluted | 2.15 | -0.33 | 3.17 | 4.33 | 1.64 |
| Normalized Diluted EPS | 2.23 | 1.80 | 3.18 | 3.67 | 2.76 |
| Average Basic Shares Outstanding | 147.20M | 146.70M | 146.60M | 146.50M | 146.10M |
| Average Diluted Shares Outstanding | 148.40M | 146.70M | 147.10M | 146.70M | 146.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |